{"component": "clause", "props": {"groups": [{"samples": [{"hash": "9hPi8PioCwi", "uri": "/contracts/9hPi8PioCwi#ultimate-parent", "label": "Merger Agreement (CVS HEALTH Corp)", "score": 34.1033554077, "published": true}], "size": 2, "snippet_links": [{"key": "the-parties-agree", "type": "clause", "offset": [0, 17]}, {"key": "party-to-this-agreement", "type": "clause", "offset": [66, 89]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [97, 116]}, {"key": "to-the-extent", "type": "clause", "offset": [130, 143]}, {"key": "terms-defined", "type": "definition", "offset": [148, 161]}, {"key": "section-41", "type": "clause", "offset": [250, 261]}, {"key": "section-42", "type": "clause", "offset": [263, 274]}, {"key": "section-43", "type": "clause", "offset": [276, 287]}, {"key": "section-44", "type": "clause", "offset": [289, 300]}, {"key": "section-45", "type": "clause", "offset": [302, 313]}, {"key": "section-46", "type": "clause", "offset": [315, 326]}, {"key": "section-49", "type": "clause", "offset": [328, 339]}, {"key": "section-62", "type": "clause", "offset": [355, 366]}, {"key": "article-ix", "type": "definition", "offset": [399, 409]}], "snippet": "The Parties agree and acknowledge that Ultimate Parent shall be a party to this Agreement solely for the purposes of Section 1.1 (to the extent the terms defined therein are used in the following Sections and Article of this Agreement) Section 3.28, Section 4.1, Section 4.2, Section 4.3, Section 4.4, Section 4.5, Section 4.6, Section 4.9, Section 4.16, Section 6.2, Section 6.12, Section 6.18 and Article IX.", "hash": "786287755b5c98239da2dc6a4c741f16", "id": 2}, {"samples": [{"hash": "8NiyIULCK9G", "uri": "/contracts/8NiyIULCK9G#ultimate-parent", "label": "Additional Facility Accession Agreement (Sunrise Communications AG)", "score": 36.1594810486, "published": true}, {"hash": "gNLKJ0HAPAG", "uri": "/contracts/gNLKJ0HAPAG#ultimate-parent", "label": "Additional Facility Agreement (Sunrise Communications AG)", "score": 35.6502380371, "published": true}, {"hash": "MeL1qCUyks", "uri": "/contracts/MeL1qCUyks#ultimate-parent", "label": "Additional Facility Ax Accession Agreement (Sunrise Communications AG)", "score": 35.6502380371, "published": true}], "size": 13, "snippet_links": [{"key": "the-definition-of", "type": "clause", "offset": [6, 23]}, {"key": "in-clause", "type": "clause", "offset": [40, 49]}, {"key": "new-paragraph", "type": "clause", "offset": [80, 93]}], "snippet": "Amend the definition of Ultimate Parent in Clause 1.1 (Definitions) by adding a new paragraph (b) as follows and renumbering the existing paragraphs accordingly:", "hash": "d78b12613a2a46c4f84312538caaffd7", "id": 1}, {"samples": [{"hash": "iEc74uXTMYR", "uri": "/contracts/iEc74uXTMYR#ultimate-parent", "label": "Additional Facility Joinder Agreement (Liberty Latin America Ltd.)", "score": 27.1149902344, "published": true}], "size": 1, "snippet_links": [{"key": "the-definition-of", "type": "clause", "offset": [14, 31]}, {"key": "annex-i", "type": "definition", "offset": [51, 58]}, {"key": "liberty-latin-america", "type": "definition", "offset": [105, 126]}], "snippet": "clause (1) of the definition of Ultimate Parent in Annex I shall be deleted and replaced as follows:\n(1) Liberty Latin America and any and all successors thereto or\u201d.", "hash": "83ce4740642e40d9ea9cd8ccc58875ae", "id": 3}, {"samples": [{"hash": "eDtl6EVMgyp", "uri": "/contracts/eDtl6EVMgyp#ultimate-parent", "label": "Merger Agreement (Clark Schwebel Holdings Inc)", "score": 18.0, "published": true}], "size": 1, "snippet_links": [{"key": "the-code", "type": "clause", "offset": [57, 65]}, {"key": "issued-and-outstanding-capital-stock", "type": "clause", "offset": [108, 144]}, {"key": "consolidated-federal-income-tax-return", "type": "definition", "offset": [184, 222]}, {"key": "directly-or-indirectly", "type": "clause", "offset": [240, 262]}], "snippet": "Equilease is a subchapter \"C\" corporation (as defined by the Code) and no corporation which owns any of the issued and outstanding capital stock of Equilease includes Equilease in its consolidated federal income tax return. Equilease owns, directly or indirectly, all of the issued and outstanding capital stock of EQ.", "hash": "c07e951910896f876549fa0e83d47200", "id": 4}, {"samples": [{"hash": "bSfWkMPPQt9", "uri": "/contracts/bSfWkMPPQt9#ultimate-parent", "label": "Offer to Purchase (GSK PLC)", "score": 37.0876112252, "published": true}], "size": 1, "snippet_links": [{"key": "business-address", "type": "definition", "offset": [10, 26]}, {"key": "principal-occupation", "type": "clause", "offset": [36, 56]}, {"key": "five-years", "type": "definition", "offset": [143, 153]}, {"key": "directors-and-executive-officers-of", "type": "clause", "offset": [161, 196]}, {"key": "the-business", "type": "clause", "offset": [265, 277]}, {"key": "all-directors", "type": "clause", "offset": [453, 466]}, {"key": "listed-below", "type": "clause", "offset": [490, 502]}, {"key": "the-united-states", "type": "definition", "offset": [519, 536]}, {"key": "chair-of-the-board-of-directors", "type": "clause", "offset": [560, 591]}, {"key": "the-chair", "type": "clause", "offset": [618, 627]}, {"key": "gsk-plc", "type": "definition", "offset": [657, 664]}, {"key": "september-2019", "type": "clause", "offset": [671, 685]}, {"key": "since-december", "type": "clause", "offset": [687, 701]}, {"key": "chief-executive-officer", "type": "clause", "offset": [722, 745]}, {"key": "advisory-role", "type": "clause", "offset": [746, 759]}, {"key": "december-2020", "type": "clause", "offset": [858, 871]}, {"key": "director-of", "type": "clause", "offset": [892, 903]}, {"key": "greater-manchester", "type": "definition", "offset": [1023, 1041]}, {"key": "august-2020", "type": "clause", "offset": [1073, 1084]}, {"key": "the-united-kingdom", "type": "clause", "offset": [1264, 1282]}, {"key": "on-the-board", "type": "definition", "offset": [1354, 1366]}, {"key": "september-2017", "type": "clause", "offset": [1488, 1502]}, {"key": "chief-commercial-officer", "type": "definition", "offset": [1535, 1559]}, {"key": "research-centre", "type": "definition", "offset": [1716, 1731]}, {"key": "chief-financial-officer", "type": "definition", "offset": [1851, 1874]}, {"key": "april-2023", "type": "clause", "offset": [2007, 2017]}, {"key": "march-2016", "type": "clause", "offset": [2024, 2034]}, {"key": "september-2022", "type": "clause", "offset": [2038, 2052]}, {"key": "a-non", "type": "clause", "offset": [2068, 2073]}, {"key": "executive-director", "type": "clause", "offset": [2074, 2092]}, {"key": "an-independent", "type": "clause", "offset": [2359, 2373]}, {"key": "november-2018", "type": "clause", "offset": [2436, 2449]}, {"key": "independent-director", "type": "definition", "offset": [2472, 2492]}, {"key": "july-2019", "type": "clause", "offset": [2596, 2605]}, {"key": "may-2020", "type": "clause", "offset": [3080, 3088]}, {"key": "april-2020", "type": "clause", "offset": [3183, 3193]}, {"key": "october-2020", "type": "clause", "offset": [3334, 3346]}, {"key": "july-2018", "type": "clause", "offset": [3877, 3886]}, {"key": "march-2018", "type": "clause", "offset": [4033, 4043]}, {"key": "the-advisory-board", "type": "definition", "offset": [4073, 4091]}, {"key": "life-sciences", "type": "definition", "offset": [4102, 4115]}], "snippet": "The name, business address, present principal occupation or employment and material occupations, positions, offices or employment for the past five years of the directors and executive officers of Ultimate Parent are set forth below. Except as otherwise indicated, the business address of each such director and executive officer is \u2587\u2587 \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587. The telephone of such office is +\u2587\u2587 \u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587. Except as otherwise indicated, all directors and executive officers listed below are citizens of the United States. \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587, Chair of the Board of Directors \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 has served as the Chair of the board of directors of GSK plc since September 2019. Since December 2025, he has held a Chief Executive Officer advisory role at Causaly Ltd. The address of Causaly Ltd. is \u2587\u2587-\u2587\u2587 \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587 \u2587\u2587\u2587. Since December 2020, he has served as a Director of Quality by Randomization Limited (trading as \u2587\u2587\u2587\u2587\u2587\u2587), the address of which is 2 New \u2587\u2587\u2587\u2587\u2587\u2587, \u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587, Salford, Greater Manchester, M3 5GS, United Kingdom. Since August 2020, he has served as a Director of \u2587\u2587\u2587\u2587\u2587 Pharmaceuticals Pvt. Ltd., the address of which is \u2587 \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587 \u2587, \u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587. \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 is a citizen of the United Kingdom. \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587, Director and Chief Executive Officer \u2587\u2587. \u2587\u2587\u2587\u2587\u2587 has served on the board of directors of GSK plc since January 2026 and has served as Chief Executive Officer of GSK plc since January 2026. From September 2017 to September 2025, he served as Chief Commercial Officer of GSK plc. From September 2017 to August 2025, he served as a Director of ViiV Healthcare Limited. The address of ViiV Healthcare Limited is GSK Medicines Research Centre, \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587, Stevenage, SG1 2NY, United Kingdom. \u2587\u2587. \u2587\u2587\u2587\u2587\u2587 is a citizen of Australia. \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587, Director and Chief Financial Officer \u2587\u2587. \u2587\u2587\u2587\u2587\u2587 has served on the board of directors of GSK plc since May 2023 and has served as Chief Financial Officer of GSK plc since April 2023. From March 2016 to September 2022, she served as a Non-Executive Director and Audit Chair of Roche Holding AG. The address of Roche Holding AG is \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587, \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587. \u2587\u2587. \u2587\u2587\u2587\u2587\u2587 is a citizen of the United Kingdom. \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 (\u2587\u2587\u2587) \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, Independent Non-Executive Director \u2587\u2587. \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 has served as an Independent Non-Executive Director of GSK plc since September 2022. Since November 2018, she has served as an Independent Director of Insmed Inc. The address of Insmed Inc. is \u2587\u2587\u2587 \u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587/\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587 \u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587. Since July 2019, she has served as an Independent Director of BioMarin Pharmaceutical Inc. The address of BioMarin Pharmaceutical Inc. is \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587 \u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587. Since April 2015, she has served as an Independent Director of Revolution Medicines, Inc. The address of Revolution Medicines, Inc. is \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587, \u2587\u2587 \u2587\u2587\u2587\u2587\u2587. \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, Senior Independent Non-Executive Director \u2587\u2587. \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 was appointed to the board of directors of GSK plc in May 2020 and has served as Senior Independent Non-Executive Director of GSK plc since July 2022. Since April 2020, he has served as a Director of Kodiak Sciences Inc. The address of Kodiak Sciences Inc. is \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587, \u2587\u2587 \u2587\u2587\u2587\u2587\u2587. Since October 2020, he has served as a Director of Biovector, Inc. The address of Biovector, Inc. is \u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587, Ardmore, PA 19003. \u2587\u2587. \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587, Non-Executive Director \u2587\u2587. \u2587\u2587\u2587\u2587\u2587\u2587 was appointed to the board of directors of GSK plc in January 2018 and has served as a Non-Executive Director of GSK plc since August 2022. Since August 2022, he has served as Chief Executive Officer, Founder and Co-Chair of the board of directors of Altos Labs, Inc.The address of Altos Labs, Inc. is \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587, \u2587\u2587 \u2587\u2587\u2587\u2587\u2587. From July 2018 to August 2021, he served as a Non-Executive Director of GRAIL, Inc. The address of GRAIL, Inc. is \u2587\u2587\u2587\u2587 \u2587\u2019\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587, \u2587\u2587 \u2587\u2587\u2587\u2587\u2587. From March 2018 to August 2021, he served on the advisory board of Verily Life Sciences LLC, the address of which is \u2587\u2587\u2587 \u2587 \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587 \u2587\u2587\u2587\u2587\u2587.", "hash": "f4ee893a98751e4e3f0107737b18f87b", "id": 5}, {"samples": [{"hash": "gq5t6c6Qoy5", "uri": "/contracts/gq5t6c6Qoy5#ultimate-parent", "label": "364 Day Credit Agreement (Pegasus Communications Corp /)", "score": 18.0, "published": true}], "size": 1, "snippet_links": [{"key": "the-stockholder", "type": "clause", "offset": [40, 55]}, {"key": "the-parent", "type": "clause", "offset": [59, 69]}, {"key": "equity-restructuring", "type": "definition", "offset": [84, 104]}, {"key": "signature-pages", "type": "clause", "offset": [130, 145]}], "snippet": "The Person that is to become or becomes the stockholder of the Parent in the Parent Equity Restructuring. [The next pages are the signature pages]", "hash": "2b4a79bec5b68f73da701317be370ac1", "id": 6}, {"samples": [{"hash": "aYevPg9DF3k", "uri": "/contracts/aYevPg9DF3k#ultimate-parent", "label": "Merger Agreement (Brocade Communications Systems Inc)", "score": 27.8364143372, "published": true}], "size": 1, "snippet_links": [{"key": "comply-with", "type": "definition", "offset": [38, 49]}, {"key": "obligations-under-this-agreement", "type": "clause", "offset": [78, 110]}, {"key": "in-accordance-with", "type": "definition", "offset": [111, 129]}, {"key": "the-terms", "type": "definition", "offset": [130, 139]}], "snippet": "Ultimate Parent shall cause Parent to comply with and perform all of Parent\u2019s obligations under this Agreement in accordance with the terms hereof.", "hash": "85db113b6ad7624bd266001e7efd7c44", "id": 7}, {"samples": [{"hash": "eEMA8aBcgXb", "uri": "/contracts/eEMA8aBcgXb#ultimate-parent", "label": "Stock Purchase Agreement (Taboola.com Ltd.)", "score": 32.6659812927, "published": true}], "size": 1, "snippet_links": [{"key": "date-hereof", "type": "clause", "offset": [10, 21]}, {"key": "at-all-times", "type": "definition", "offset": [27, 39]}, {"key": "prior-to-the-closing", "type": "clause", "offset": [40, 60]}, {"key": "ultimate-parent-entity", "type": "definition", "offset": [105, 127]}, {"key": "in-accordance-with", "type": "definition", "offset": [144, 162]}, {"key": "hsr-act", "type": "clause", "offset": [167, 174]}, {"key": "the-rules", "type": "clause", "offset": [179, 188]}, {"key": "of-seller", "type": "clause", "offset": [213, 222]}], "snippet": "As of the date hereof, and at all times prior to the Closing, STG III, L.P. (\u201cUPE\u201d) is and shall be the \u201cultimate parent entity\u201d (as determined in accordance with the HSR Act and the rules promulgated thereunder) of Seller.", "hash": "f5ece3090ee38b8dbbf1aec9abfc2bd1", "id": 8}, {"samples": [{"hash": "cQctyqGvRFQ", "uri": "/contracts/cQctyqGvRFQ#ultimate-parent", "label": "Merger Agreement (Cross Country Healthcare Inc)", "score": 35.9240264893, "published": true}], "size": 1, "snippet_links": [{"key": "ultimate-parent-entity", "type": "definition", "offset": [18, 40]}, {"key": "hsr-act", "type": "clause", "offset": [74, 81]}, {"key": "directly-or-indirectly", "type": "clause", "offset": [91, 113]}, {"key": "consolidated-assets", "type": "clause", "offset": [132, 151]}, {"key": "the-business", "type": "clause", "offset": [156, 168]}, {"key": "subsidiary-of", "type": "definition", "offset": [313, 326]}], "snippet": "Guarantor is the \u201cultimate parent entity\u201d (as such term is defined in the HSR Act) of, and directly or indirectly holds 100% of the consolidated assets of, the business of Aya Healthcare, Inc., Parent and their respective Subsidiaries (including all of the business of \u201cAya Healthcare\u201d). Parent is a wholly owned Subsidiary of Guarantor.", "hash": "e13b6ee41cedba53cddd63d163223c4c", "id": 9}, {"samples": [{"hash": "hJiuXrehLrd", "uri": "/contracts/hJiuXrehLrd#ultimate-parent", "label": "Asset Purchase Agreement (Kendle International Inc)", "score": 18.0, "published": true}], "size": 1, "snippet_links": [{"key": "the-purchaser", "type": "definition", "offset": [0, 13]}, {"key": "wto-investor", "type": "clause", "offset": [44, 56]}, {"key": "investment-canada-act", "type": "clause", "offset": [80, 101]}], "snippet": "The Purchaser is ultimately controlled by a WTO Investor for the purpose of the Investment Canada Act.", "hash": "76ceaff20e3cdfc80bcc4e8938a545d3", "id": 10}], "next_curs": "ClgSUmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjQLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ihh1bHRpbWF0ZS1wYXJlbnQjMDAwMDAwMGEMogECZW4YACAA", "clause": {"size": 25, "children": [], "title": "Ultimate Parent", "parents": [["definitions", "Definitions"], ["miscellaneous", "Miscellaneous"], ["general-provisions", "General Provisions"], ["government-consents", "Government Consents"], ["purchase-and-sale-of-assets", "Purchase and Sale of Assets"]], "id": "ultimate-parent", "related": [["holdings", "Holdings", "Holdings"], ["parent", "Parent", "Parent"], ["the-borrower", "The Borrower", "The Borrower"], ["organization-subsidiaries", "Organization; Subsidiaries", "Organization; Subsidiaries"], ["holding-companies", "Holding Companies", "Holding Companies"]], "related_snippets": [], "updated": "2026-02-07T05:29:46+00:00", "also_ask": ["How should 'Ultimate Parent' be precisely defined to avoid ambiguity or loopholes?", "What negotiation leverage does the definition of 'Ultimate Parent' provide in group company structures?", "What are the key risks if the 'Ultimate Parent' is misidentified or changes post-signing?", "How do courts interpret 'Ultimate Parent' in cross-border or multi-jurisdictional disputes?", "What drafting elements are essential to ensure enforceability and clarity of the 'Ultimate Parent' clause?"], "drafting_tip": "Define 'Ultimate Parent' precisely to avoid ambiguity; specify identification criteria to ensure enforceability; reference relevant corporate structures to prevent misinterpretation.", "explanation": "The \"Ultimate Parent\" clause defines the entity that sits at the top of a corporate group\u2019s ownership structure, having direct or indirect control over all subsidiaries. In practice, this clause identifies the highest-level parent company, which is often relevant for determining responsibility, compliance, or reporting obligations within a group of related companies. By clearly specifying which entity is considered the ultimate parent, the clause ensures clarity in contractual relationships and helps avoid disputes about control or liability within complex corporate structures."}, "json": true, "cursor": ""}}